San Diego flood victims eligible for up to $20K in mortgage aid through state fund
SAN DIEGO (FOX 5/KUSI) — San Diego flood victims may now qualify for a new state mortgage relief program meant to ease some of the financial burden of natural disasters.
Nearly a year and half after historic flooding inundated parts of San Diego, some residents in hard hit areas are still rebuilding and the bills keep adding up.
'The original estimates that I've received was $435,000. So I'm a long way off from that,' said Southcrest resident Greg Montoya, whose Beta Street home is one of several severely damaged by the historic rainstorm in January 2024.
Montoya said he's already spent more than $100,000. The majority of the cost was covered by flood insurance and some from FEMA dollars, but the rest out of pocket.
A new program called CalAssist Mortgage Fund, consisting of $105 million, is giving him hope for a little extra help.
Eligible homeowners whose homes were destroyed or left uninhabitable by a disaster between January 2023 and January 2025 can apply for three months of mortgage payments up to $20,000.
Applicants' annual income in San Diego County must be below $172,000 to qualify.
'The application is really easy. If you have all the documents, it takes less than 30 minutes to apply. The documents are all very easily available online, like a mortgage statement or your bank account statement,' said Rebecca Franklin, Chief Deputy Director at the California Housing Finance Agency which oversees the fund.
The program operates on a first come first serve basis and Franklin said the goal is to help 10,000 households statewide.
When it comes to the hard-hit Southcrest neighborhood, some are done with repairs.
'Fortunately for me I was able to find a contractor that would do all the work for the $250,000 which to me is a lot of money,' said neighbor Josh Roche.
Roche considers himself lucky that insurance came through, but he and his family still had out of pocket expenses.
'Especially immediately you know when we were completely displaced the city hadn't started their program where we were staying in the hotels. A lot of extra commuting. A lot of time lost from work,' Roche said.
While residents said they're grateful for any help, some are still pointing the finger.
'The city should find the means to make everybody complete and start paying people because it was preventable,' said neighbor Greg Montoya.
Residents can apply for the CalAssist Mortgage Fund starting Thursday. More information can be found here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
Great Lakes Stock Trading at a Discount: Is It Buy Time Now?
Great Lakes Dredge & Dock Corporation's GLDD current valuation is enticing for investors. Currently, the stock is trading below its industry peers with a forward 12-month price-to-earnings (P/E) ratio of 12.43X, as evidenced by the chart below. Moreover, the discounted valuation of GLDD compares favorably with a few of the other market players, including Orion Group Holdings, Inc. ORN, Quanta Services, Inc. PWR and Granite Construction Incorporated GVA. The 12-month P/E ratios of Orion Group, Quanta and Granite Construction are 31.69X, 32.73X and 13.98X, respectively. Image Source: Zacks Investment Research The discounted valuation of GLDD stock, compared with its peers, advocates for an attractive entry point for investors. That said, in the long term, the valuation could move toward a premium, given the strong market fundamentals backing the company's revenue visibility and Texas-based dredging services provider is mainly gaining from large-scale capital and coastal protection projects compared with mainstream maintenance dredging. Thanks to its resilience in offering such services, it enjoys a competitive edge in the market. Moreover, its new build program, proposed in 2020, catalyzes its ability to offer such services efficiently and expand the margins in the process. With such favorable market fundamentals and its in-house capabilities, the company is consistently able to enhance its liquidity position, thus increasing space for strategic long-term investments and shareholder GLDD's shares have soared 34.6% in the past three months, outperforming the Zacks Building Products - Heavy Construction industry, the broader Zacks Construction sector and the S&P 500 index. The detailed price performance can be studied from the chart below. Image Source: Zacks Investment Research Let's delve deeper into understanding the factors driving GLDD's momentum. Great Lakes is significantly benefiting from the robust demand trends for large-scale capital and coastal protection projects. This is because it houses the specifications that are required to offer these services, differing from maintenance dredging, allowing it a competitive advantage over other market players like Orion Group, which mainly offers mainstream dredging services. As of March 31, 2025, GLDD's substantial dredging backlog was $1 billion compared with $879.4 million as of last year's first quarter, with capital and coastal protection projects accounting for 95% of the total dredging main driver for coastal restoration projects is the increased government funding for infrastructure projects, at the state and federal levels, due to the U.S. Army Corps of Engineers or FEMA-backed initiatives backed by the Infrastructure Investment and Jobs Act (IIJA) and the Inflation Reduction Act (IRA). These projects being government-funded, reduce payment failure risks, and with being larger in scale and having longer duration, it also ensures efficient asset utilization. Such characteristics of these projects not only boost the company's revenue visibility but also foster its margin growth. Tailwinds from public infrastructure spending are also aiding other market players like Quanta and Granite Construction. Proposed in 2020, the new build program was approved and rolled out to renew and modernize GLDD's fleet. Through this program, the company mainly aims to stand tall for offering services in coastal restoration and shoreline protection, establishing a resilient business model. As part of this program, the company is currently undergoing construction of Acadia, the first U.S.-flagged Jones Act-compliant subsea rock installation vessel, which is expected to be delivered by the first quarter of 2026. Acadia will be considered for domestic and international offshore wind projects alongside critical subsea infrastructure protection the newest hopper dredge, the Amelia Island (expected delivery in the third quarter of 2025) and the Galveston Island have been designed specifically by GLDD to work efficiently in shallow and narrow waters along the U.S. coastlines, specifically for coastal protection projects such as beach restoration, wetlands improvements and Barrier Island construction. With the program wrapping up by the end of 2025 or the beginning of 2026, the company expects to witness incremental revenue trends and increased free cash flow thereafter. Given the current market uncertainties and an inflationary scenario, maintaining a substantial liquidity position alongside making strategic business investments is a strenuous task. Great Lakes is managing this job just fine by leveraging its increasing top line and almost concluding its investment of March 31, 2025, GLDD had cash and cash equivalents of $11.3 million, up from $10.2 million at 2024-end. Net cash from operating activities, as of the same period, was $60.9 million, up year over year from $38.4 million, attributable to higher earnings in the period and an increase in billings above contract revenues. With no debt maturities until 2029 and liquidity of more than $300 million, the company has a stable liquidity position to function in an uncertain market scenario. GLDD's earnings estimates for 2025 and 2026 have trended upward in the past 60 days by 39.1% to 96 cents per share and 11.8% to 95 cents, respectively. The estimated figure for 2025 reflects 14.3% year-over-year growth, with the same for 2026 indicating a 0.4% inch-down. EPS Trend Image Source: Zacks Investment Research Technical indicators suggest a continued strong performance for Great Lakes. From the graphical representation given below, it can be observed that GLDD stock is riding above both the 50-day simple moving average (SMA) and the 200-day SMA, signaling a bullish trend. The technical strength underscores positive market sentiment and confidence in GLDD's financial health and prospects. 50 & 200-Day Moving Averages Image Source: Zacks Investment Research As discussed above, strong demand trends for large-scale capital and coastal protection projects, backed by a favorable government funding scenario in the US, are the main driving factors for Great Lakes' revenues and margins. The company's competitive edge over its peers for offering these services, thanks to its multi-year new build program, is an added catalyst amid the favorable market optimism regarding GLDD stock is reflected in three of the three recommendations pointing at a "Strong Buy'. Image Source: Zacks Investment Research Thus, based on the above discussion and trends of the technical indicators, this Zacks Rank #1 (Strong Buy) stock is a decent choice to be added to the portfolio for now. You can see the complete list of today's Zacks #1 Rank stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Quanta Services, Inc. (PWR) : Free Stock Analysis Report Orion Group Holdings, Inc. (ORN) : Free Stock Analysis Report Great Lakes Dredge & Dock Corporation (GLDD) : Free Stock Analysis Report Granite Construction Incorporated (GVA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
10 hours ago
- Yahoo
Multispecific Antibodies Market, Drug Sales, Dosage, Price & Clinical Trials Report: Multispecific Antibodies Market to Surpass USD 50 Billion by 2030
Explore the booming Global Multispecific Antibodies Market set to surpass USD 50 billion by 2030. Key highlights include sales insights, approved drugs, and clinical trials from over 700 antibodies. Significant contributors like Roche and rising players ensure ongoing innovation in this dynamic biopharma sector. Dublin, June 13, 2025 (GLOBE NEWSWIRE) -- The "Global Multispecific Antibodies Market, Drug Sales, Dosage, Price & Clinical Trials Insight 2030" report has been added to Multispecific Antibodies Market, Drug Sales, Dosage, Price & Clinical Trials Insight 2030 Report Highlights: Global Multispecific Antibodies Market Opportunity By 2030: > USD 50 Billion Global Multispecific Antibodies Market Sales In 2024: > USD 12 Billion Number Of Approved Multispecific Antibodies: 18 Global & Regional Trends Insight Approved Antibodies Global, Regional, Annual & Quarterly Sales Insight Approved Antibodies Dosage & Pricing Insight Comprehensive Insight On All Antibodies In Clinical Trials By Company, Country, Indication & Phase Number Of Multispecific Antibodies: In Clinical Trials: > 700 Multispecific antibodies market globally has been one of the most energetic and fast growing sectors in the biopharmaceutical business as a result of therapeutic breakthroughs and growing acceptance of their ability to treat complicated pathologies by targeting multiple pathways simultaneously. As of May 2025, 18 multispecific antibodies have gained regulatory approval globally, all of which are bispecific constructs, a monumental milestone in the history of targeted therapeutics. This expanding portfolio boasts trailblazing drugs like Blincyto, the first bispecific antibody to gain approval, and Hemlibra, which was the first bispecific antibody to be approved for a non-cancer indication. The latest entrant to this therapeutic pipeline is Regeneron's Lynozyfic, which received marketing approval in April 2025 for the treatment of multiple myeloma, with evidence of ongoing momentum in the segment. The range of approved multispecific antibodies mirrors the flexibility of this therapeutic modality across various disease indications and patient bases. Rybrevant is another key breakthrough as the first bispecific antibody for a solid tumor, whereas China based Akeso's Cadonilimab is especially noteworthy for being solely approved bispecific antibody intended to target two immune checkpoints at once and becoming the first China developed bispecific antibody to gain regulatory approval. This regional variation in development emphasizes the world nature of innovation in this sector, with input from both mature pharmaceutical markets and developing biotechnology centers. The regulatory environment is still changing at a rapid pace, with further approvals expected in the near future. The FDA is also evaluating marketing applications for Odronextamab and Linvoseltamab, both of which have already received approval in the EU for follicular lymphoma and diffuse large B-cell lymphoma, and multiple myeloma, respectively. Such transatlantic regulatory advancements reflect the growing acceptability and trust in multispecific antibody technologies by global regulatory bodies. Market performance has been extremely strong, with global multispecific antibodies market sales in 2024 amounting to over US$ 12.6 Billion, followed by first quarter 2025 sales of over US$ 3.46 Billion. The US is the largest contributor to these sales, highlighting the maturity and acceptance of the market in this prime geography. Roche's mature products, Hemlibra and Vabysmo, lead the market share, with over half of total sales, emphasizing the value of first mover benefit and effective market entry strategies in this competitive market. The pipeline for development is an even more daunting picture, with more than 900 multispecific antibodies already in various stages of development. Oncology is leading this pipeline, both due to the traditional priority of multispecific antibody development and due to the large unmet medical needs in cancer treatment. However, pipeline diversity is not confined to oncology alone with promising candidates being identified in autoimmune and inflammatory diseases and neurological disorders as well, indicating an expanding therapeutic horizon that has the potential to dramatically expand market opportunities. Major industry players behind this innovation are well established pharma giants like Amgen, AstraZeneca, Genentech, and Regeneron, as well as new biotech firms like ABL Bio, Harbour BioMed, Innovent Biologics, Merus, and Zymeworks. This combination of well established and new players provides a vibrant competitive landscape that ensures ongoing innovation and technological progress. Strategic alliances continue to influence the development of the market, such as in the April 2025 alliance of Boehringer Ingelheim and Cue Biopharma for the development of CUE-501, a bispecific candidate that attacks pathogenic B cells via virus-specific memory T cells. The alliance, involving a US$ 12 Million upfront payment and possible milestone payments of up to US$ 345 Million, illustrates the high financial investment that companies are undertaking to drive multispecific antibody technologies, specifically in autoimmune indications where existing treatments are still inadequate. Regulatory encouragement of innovation continues to be robust, with the FDA's April 2025 fast track designation of ISB 2001, an Ichnos Glenmark Innovation investigational trispecific T-cell engager for relapsed or refractory multiple myeloma, reflecting ongoing regulatory enthusiasm for moving multispecific antibody technologies forward that treat important unmet medical needs. As a result of these ongoing innovations, the global multispecific antibody market is expected to grow rapidly and is on track to become one of the most important segments within the pharmaceutical industry. Key Topics Covered: 1. Introduction to Next Generation Multispecific Antibodies 2. Next Generation Multispecific Antibody Current Clinical Development & Future Commercialization Outlook2.1 Current Market Overview2.2 Future Commercialization Opportunity2.3 Collaborations, License Agreements, Investments & Acquisitions2.4 Next Generation Multispecific Antibody Proprietary Technologies By Company 3. Next Generation Multispecific Antibody Clinical Trends by Indication3.1 Cancer3.2 Hematological Disorders3.3 Microbial Infections3.4 Autoimmune & Inflammatory Disorders3.5 Ocular Diseases 4. Next Generation Multispecific Antibody Clinical Development & Market Trends by Region4.1 US4.2 EU4.3 China4.4 UK4.5 Japan4.6 Australia4.7 South Korea4.8 Canada 5. Approved Multispecific Antibodies - Clinical Overview, Pricing & Dosage Insight5.1 Overview5.2 Clinical Overview, Pricing & Dosage Insight 6. Approved Multispecific Antibodies - Sales Insight (2020 - Q1'2025) 7. Global Multispecific Antibodies Clinical Trials Overview 8. Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase8.1 Research8.2 Preclinical8.3 Phase-I8.4 Phase-I/II8.5 Phase-II8.6 Phase-II/III8.7 Phase-III8.8 Preregistration8.9 Registered 9. Marketed Bispecific Antibodies Clinical Insight By Company, Country & Indication 10. Global Trispecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase10.1 Research10.2 Preclinical10.3 Phase I10.4 Phase I/II10.5 Phase II/III 11. Tetraspecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase11.1 Preclinical11.2 Phase I11.3 Phase I/II11.4 Phase II 12. Competitive Landscape AbbVie ABL Bio Abzyme Therapeutics Affimed Therapeutics Akeso Biopharma Alligator Bioscience Amgen Antibody Therapeutics APITBIO Astellas Pharma AstraZeneca Aptevo Therapeutics BioAtla Biocytogen Pharmaceuticals Biosion EpimAb Biotherapeutics FutureGen Biopharmaceutical Genentech Genmab Genor Biopharma Gensun Biopharma Harbour BioMed IGM Biosciences I-MAB Biopharma ImmuneOnco Biopharma ImmunoPrecise Antibodies Innate Pharma Innovent Biologics Invenra Johnson & Johnson Kenjockety Biotechnology LaNova Medicines Limited Light Chain Bioscience Linton Pharm Lyvgen Biopharma MacroGenics Merck Merus ModeX Therapeutics (OPKO Health) Molecular Partners NovaRock Biotherapeutics Numab OPKO Health Pfizer Regeneron Pharmaceuticals Revitope Roche Sanofi Sichuan Baili Pharmaceutical SystImmune Virtuoso Therapeutics Xencor Y-Biologics Zhejiang Shimai Pharmaceutical Zymeworks For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
San Diego's inflation rate goes up again. What costs are going up?
(Above: Nexstar Media Wire explainer video on the differences between inflation, disinflation and deflation) SAN DIEGO (FOX 5/KUSI) — San Diego's inflation rate went up again in May, according to data released Wednesday by the U.S. Bureau of Labor Statistics. The bureau's Consumer Price Index reported the inflation rate in San Diego, which encompasses all of the county, was 3.8% in May, the highest in the nation. It also had the highest inflation in March, tied at 3.8% with New York. More than 160 affordable housing units opened at old Mission Valley hotel People saw prices go up across most areas, but the expenditures that saw the highest percentages of change in the past two months included dairy and related products (up 2.4%), transportation (2%) and medical care (2.2%). From May 2024 to May 2025, the areas that saw the biggest gains were transportation (2.5%), medical care (3.7%), housing (4.9%), dining out (6.9%) and tuition, school fees and child care (8.7%). This comes after a recent report using data collected by Child Care Aware showed the costs associated with child care were more expensive for families than those spent on housing in the state of California in 2024. Meanwhile, the cost of motor fuel went down 8% from the same month last year. In fact, the inflation rate has gone down about 1% between April and May. Another area that saw a significant decrease between May of 2024 and this past May was the cost of apparel (-7.6%). Cereals and baked goods also saw lower inflation rates compared to May of last year and month-over-month between April and May of this year. The full Consumer Price Index dataset can be found here. The nationwide inflation rate was just 0.1% in May. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
